Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Attention deficit hyperactivity disorder (ADHD): US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

ADHD: the short answer

The US FDA has approved two medicines covered on this page for ADHD, each for a specific group of patients: Qelbree and Onyda XR. On 17 October 2026, none of them was on the Saudi or Abu Dhabi register we checked. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Qelbree and Onyda XR.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is ADHD?

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder. It involves trouble paying attention, trouble controlling impulsive behavior, and being overly active. It is usually first diagnosed in childhood and often lasts into adulthood, although some people are not diagnosed until they are adults.[1, 2]

There are three types: mostly inattentive, mostly hyperactive-impulsive, and combined, which is the most common type. Many people show some of these behaviors at times, but in ADHD they are frequent, happen across settings such as home and school, and interfere with daily life.[1, 2]

ADHD is one of the most common disorders diagnosed in children. Treatment can include medicines, behavioral therapy and support at home and school.[2, 1]

ADHD in the Gulf

Researchers in the United Arab Emirates have published on ADHD in recent years, including a national study of undiagnosed ADHD symptoms in young adults, work on healthcare use by children with ADHD, and a study of tele-mental health care for children with ADHD.[3, 4, 5]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 0 of 2 were listed in Saudi Arabia and 0 of 2 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[6, 7]

US FDA-approved medicines for ADHD

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Qelbree (viloxazine)
    US FDA-approved for ADHD in adults and children 6 years and older. It is a non-stimulant capsule taken by mouth.[8]
    Current US label version: 5 October 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
  • Onyda XR (clonidine extended-release oral suspension)
    US FDA-approved for ADHD in children 6 years and older, on its own or added to stimulant medicines. It is an extended-release oral suspension of clonidine, a non-stimulant.[9]
    Current US label version: 11 April 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, Bahrain, Egypt, Turkey

How families in the Gulf can access treatment

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[10, 11] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for ADHD

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for ADHD?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Qelbree and Onyda XR. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Qelbree available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (Department of Health drug code list): not found. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Qelbree?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Are there non-stimulant medicines for ADHD?

Yes. Qelbree and Onyda XR are US-approved non-stimulant options. Onyda XR can also be added to a stimulant in children 6 and older. The child's doctor decides what fits.

Sources for the condition-specific answers: [8, 9]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. MedlinePlus (US National Library of Medicine): Attention Deficit Hyperactivity Disorder
  2. National Institute of Mental Health (NIMH): Attention-Deficit/Hyperactivity Disorder (ADHD)
  3. Al-Yateem N, et al. Prevalence of Undiagnosed Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in the Young Adult Population of the United Arab Emirates: A National Cross-Sectional Study. J Epidemiol Glob Health. 2024 (PubMed 38079098)
  4. Almai AM, et al. Healthcare utilisation in the United Arab Emirates for children with attention-deficit hyperactivity disorder and comorbidities. BJPsych Int. 2023 (PubMed 37531226)
  5. Albanna A, et al. Effectiveness of collaborative tele-mental health care for children with attention deficit hyperactivity disorder in United Arab Emirates. East Mediterr Health J. 2023 (PubMed 37776136)
  6. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  7. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  8. DailyMed: QELBREE (viloxazine) US prescribing information, label version 5 October 2026
  9. DailyMed: ONYDA XR (clonidine extended-release oral suspension) US prescribing information, label version 11 April 2025
  10. SFDA: Special Access Program (SAP) guidance, version 1.0
  11. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp